Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of the Immunogenicity and Efficacy of HBsAg Vaccine in combination with standard antiviral therapy in patients who have been treated with HB110E Hepatitis B DNA vaccine

Next Previous
X
Search
Trial Profile

Study of the Immunogenicity and Efficacy of HBsAg Vaccine in combination with standard antiviral therapy in patients who have been treated with HB110E Hepatitis B DNA vaccine

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GX 110 (Primary) ; Entecavir
  • Indications Hepatitis B
  • Focus Pharmacodynamics
  • Sponsors Genexine

    • Most Recent Events

    • 03 Jan 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov. record
    • 20 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 08 May 2013 New source identified and integrated (Clinical Research Information Service (CriS) - Republic of Korea: KCT0000713)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top